Joel Greenblatt’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $62.6M | Buy |
371,568
+11,432
| +3% | +$1.7M | 0.15% | 109 |
|
|
2026
Q1 | $47.4M | Buy |
360,136
+191,564
| +114% | +$25.4M | 0.15% | 129 |
|
|
2025
Q4 | $23.9M | Buy |
168,572
+32,218
| +24% | +$4.67M | 0.09% | 314 |
|
|
2025
Q3 | $19.1M | Buy |
136,354
+45,225
| +50% | +$6.13M | 0.08% | 334 |
|
|
2025
Q2 | $11.5M | Buy |
91,129
+60,106
| +194% | +$6.89M | 0.07% | 427 |
|
|
2025
Q1 | $3.43M | Buy |
31,023
+25,309
| +443% | +$3.21M | 0.03% | 634 |
|
|
2024
Q4 | $780K | Sell |
5,714
-9,603
| -63% | -$1.19M | 0.01% | 988 |
|
|
2024
Q3 | $1.76M | Sell |
15,317
-22,962
| -60% | -$3.15M | 0.02% | 760 |
|
|
2024
Q2 | $5.27M | Buy |
38,279
+32,975
| +622% | +$4.52M | 0.07% | 413 |
|
|
2024
Q1 | $732K | Sell |
5,304
-234
| -4% | -$32K | 0.01% | 935 |
|
|
2023
Q4 | $730K | Buy |
5,538
+480
| +9% | +$55.3K | 0.01% | 875 |
|
|
2023
Q3 | $569K | Sell |
5,058
-355
| -7% | -$37.4K | 0.01% | 940 |
|
|
2023
Q2 | $510K | Sell |
5,413
-2,180
| -29% | -$213K | 0.01% | 963 |
|
|
2023
Q1 | $769K | Sell |
7,593
-236
| -3% | -$24.6K | 0.02% | 822 |
|
|
2022
Q4 | $935K | Buy |
7,829
+2,204
| +39% | +$258K | 0.03% | 703 |
|
|
2022
Q3 | $597K | Buy |
5,625
+29
| +0.5% | +$2.94K | 0.02% | 810 |
|
|
2022
Q2 | $545K | Sell |
5,596
-1,427
| -20% | -$132K | 0.02% | 759 |
|
|
2022
Q1 | $658K | Buy |
7,023
+4,465
| +175% | +$378K | 0.02% | 706 |
|
|
2021
Q4 | $218K | Buy |
+2,558
| New | +$235K | 0.01% | 1055 |
|
|
2020
Q4 | – | Sell |
-18,712
| Closed | -$1.8M | – | 1069 |
|
|
2020
Q3 | $1.8M | Buy |
18,712
+5,870
| +46% | +$679K | 0.06% | 386 |
|
|
2020
Q2 | $1.57M | Sell |
12,842
-6,363
| -33% | -$703K | 0.05% | 457 |
|
|
2020
Q1 | $1.66M | Sell |
19,205
-10,460
| -35% | -$1.02M | 0.05% | 445 |
|
|
2019
Q4 | $3.19M | Buy |
29,665
+15,730
| +113% | +$1.65M | 0.06% | 366 |
|
|
2019
Q3 | $1.26M | Buy |
13,935
+3,431
| +33% | +$321K | 0.02% | 540 |
|
|
2019
Q2 | $887K | Sell |
10,504
-8,828
| -46% | -$725K | 0.01% | 658 |
|
|
2019
Q1 | $1.7M | Buy |
19,332
+2,956
| +18% | +$247K | 0.02% | 525 |
|
|
2018
Q4 | $1.17M | Sell |
16,376
-7,246
| -31% | -$694K | 0.02% | 601 |
|
|
2018
Q3 | $2.9M | Buy |
23,622
+16,209
| +219% | +$1.84M | 0.04% | 438 |
|
|
2018
Q2 | $728K | Buy |
+7,413
| New | +$664K | 0.01% | 631 |
|
Other funds holding NBIX
Joel Greenblatt's NBIX Position: Q2 2026 in Review
Joel Greenblatt increased its Neurocrine Biosciences (NBIX) stake by 3.2% in Q2 2026, buying an estimated $1.7M and bringing the position to 371,568 shares worth $62.6M. The position accounts for 0.15% of the portfolio, ranked #109.
Joel Greenblatt first reported a position in NBIX in Q2 2018 and has held it in 29 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Joel Greenblatt held 371,568 shares of Neurocrine Biosciences worth $62.6M as of Q2 2026.
- Joel Greenblatt bought 11,432 Neurocrine Biosciences shares in Q2 2026, an estimated $1.7M.
- Neurocrine Biosciences made up 0.15% of Joel Greenblatt's portfolio in Q2 2026, its #109 holding.
- Joel Greenblatt first reported a position in Neurocrine Biosciences in Q2 2018 and has held it in 29 quarters since.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.